[Tobacco, alcohol, marijuana and pregnancy: which women are at risk?].

Aim: Substance use during pregnancy is an important health issue in view of the risks to the unborn child. Predictive factors related to risk behaviors need to be assessed in order to develop prevention strategies. This assessment can also elucidate the relationship between prenatal exposure to substances and the construction of social inequalities in health early in the life course.

[Pregnancy and poly-drug use: changes in patient population and care, 1999-2008].

Changes in drug use in the general French population over the last decade have also been observed among pregnant women. There have also been significant changes in the treatment of substance users. Data relating to maternal drug use and the treatment of drug-using mothers were collected based on a retrospective cohort of 170 newborns with mothers using at least two different substances.

Pregnancy under high-dose buprenorphine.

Objective: This study was first conducted to compare the consequences of the use of methadone and high-dose buprenorphine in pregnancy in France and secondly to describe the heterogeneity of women under high-dose buprenorphine. This paper focuses on the second point only.

Study Design: From October 1998 to September 1999, data on pregnancy, delivery outcomes and neonatal parameters were collected for 251 addicted women on methadone or high-dose buprenorphine (HDB) substitution followed in 35 hospitals and clinics in continental France.

Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution.

Specialized prenatal care and substitution programs improve the perinatal prognoses of pregnant drug-abusers and their infants. Although methadone is well documented, little is known about high-dose buprenorphine (HDB). This prospective, multicenter (n = 35) observational study included 259 women on maintenance during pregnancy: 39% on methadone and 61% on HDB.